Will KVUE stock price trade above $20 per share by June 30, 2026?

KVUE's price is primarily a function of merger-closing probability and K-C stock price (0.14625 shares per KVUE share). Deal implied value was ~$21.01 at announcement. For KVUE to trade above $20, the market needs to assign >~95% probability to deal closing at current terms. Given our estimate of ~72% closing probability by year-end 2026, plus the possibility the deal closes in Q1 2027, the effective closing probability is higher than 72% (closer to 80-85% including Q1 2027). A $20 target with an ~$21 deal value implies a ~5% deal spread, which is reasonable for a deal 3-9 months from closing. The main risk is K-C stock price decline reducing the stock component of consideration.

The resolution requires KVUE to trade above $20 on ANY day through June 30, 2026 — this is easier to achieve than sustaining above $20. Even a single day of optimism (e.g., FTC clearance announcement) would trigger YES. However, we don't know the current KVUE price — if it's already trading near $20, the probability is higher; if it's at $17-18, it needs a catalyst. The K-C stock price component creates additional volatility. Deal spreads in the current environment tend to be wider than historical norms. 62% probability, with low confidence due to unknown current price.

As merger closing approaches, deal spreads typically narrow. If FTC clearance comes in Q2 2026, KVUE would very likely trade above $20 on that news. The 3-month window (March 21 - June 30) provides multiple catalysts: FTC decision, K-C earnings, KVUE earnings, IFP sale progress. Any positive regulatory signal would likely push KVUE toward deal value. The probability primarily reflects the likelihood of at least one significant positive catalyst within 3 months, which is reasonably high.

Without knowing the current KVUE price, this is challenging. The deal spread dynamics suggest KVUE should trade between $18.50-$20.50 depending on the market's assessment of deal risk. If KVUE is currently at $19+, any positive news would push it above $20. If KVUE is at $17-18, it would need significant positive catalysts. The 'any day above $20' criterion is more generous than a point-in-time requirement. Low confidence due to price uncertainty.

The deal value of ~$21 provides a strong attractor. Merger arbitrage funds typically close the spread as confidence in deal completion grows. With overwhelming shareholder support and committed financing, the primary uncertainty is FTC timeline. If FTC review progresses positively in Q2 2026, KVUE should trade above $20. The question is essentially 'will there be at least one positive regulatory signal in the next 3 months?' — which is more likely than not but far from certain.

I'm more cautious. Deal spreads have been wider than historical averages in recent years. FTC reviews can take longer than expected, keeping spreads wide. If the FTC is still in review mode through June 2026 without a clearance signal, KVUE may stay in the $18-19 range. The Tylenol litigation overhang adds additional discount. 58% probability, reflecting meaningful uncertainty about whether a sufficiently positive catalyst occurs within the 3-month window.

Deal value ~$21, any single day above $20 needed. As deal progresses toward H2 2026 close, spread should narrow. Multiple catalysts possible in 3-month window. 65% probability.

Unknown current price makes this uncertain. If KVUE is near $19-20, any positive news gets it over $20. If at $17-18, needs bigger catalyst. Merger arb dynamics favor convergence toward deal value. 60% probability with low confidence.

Strong deal fundamentals suggest spread should narrow. Three months provides enough time for at least one positive catalyst. However, FTC review uncertainty could keep spread wider than normal. 62% probability for KVUE crossing $20 at least once by June 30.